1qkt: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
The crystal structure of a triple cysteine to serine mutant ERalpha, ligand-binding domain (LBD), complexed with estradiol, shows that despite, the presence of a tightly bound agonist ligand, the protein exhibits an, antagonist-like conformation, similar to that observed in raloxifen and, 4-hydroxytamoxifen-bound structures. This mutated receptor binds estradiol, with wild type affinity and displays transcriptional activity upon, estradiol stimulation, but with limited potency (about 50%). This partial, activity is efficiently repressed in antagonist competition assays. The, comparison with available LBD structures reveals key features governing, the positioning of helix H12 and highlights the importance of cysteine, residues in promoting an active conformation. Furthermore the present, study reveals a hydrogen bond network connecting ligand binding to protein, trans conformation. These observations support a dynamic view of H12, positioning, where the control of the equilibrium between two stable, locations determines the partial agonist character of a given ligand.
The crystal structure of a triple cysteine to serine mutant ERalpha ligand-binding domain (LBD), complexed with estradiol, shows that despite the presence of a tightly bound agonist ligand, the protein exhibits an antagonist-like conformation, similar to that observed in raloxifen and 4-hydroxytamoxifen-bound structures. This mutated receptor binds estradiol with wild type affinity and displays transcriptional activity upon estradiol stimulation, but with limited potency (about 50%). This partial activity is efficiently repressed in antagonist competition assays. The comparison with available LBD structures reveals key features governing the positioning of helix H12 and highlights the importance of cysteine residues in promoting an active conformation. Furthermore the present study reveals a hydrogen bond network connecting ligand binding to protein trans conformation. These observations support a dynamic view of H12 positioning, where the control of the equilibrium between two stable locations determines the partial agonist character of a given ligand.


==Disease==
==Disease==
Line 21: Line 21:
[[Category: Moras, D.]]
[[Category: Moras, D.]]
[[Category: Ruff, M.]]
[[Category: Ruff, M.]]
[[Category: SPINE, Structural.Proteomics.in.Europe.]]
[[Category: SPINE, Structural Proteomics in Europe.]]
[[Category: Wurtz, J.M.]]
[[Category: Wurtz, J M.]]
[[Category: EST]]
[[Category: EST]]
[[Category: agonism]]
[[Category: agonism]]
Line 33: Line 33:
[[Category: structural proteomics in europe]]
[[Category: structural proteomics in europe]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:00:47 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:40:43 2008''